|  | RMST at times (years) | | | | Survival proportions | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Treatment | Source | 4 | 8 | 15 | 4 | 8 | 15 |
| FC | Observed | 3.56 | 5.99 |  | 0.77 | 0.41 |  |
|  | Semi-Markov | 3.50 | 5.47 | 6.46 | 0.70 | 0.30 | 0.05 |
|  | Microsimulation | 3.57 | 6.26 | 9.13 | 0.78 | 0.55 | 0.31 |
| RFC | Observed | 3.68 | 6.54 |  | 0.84 | 0.61 |  |
|  | Semi-Markov | 3.64 | 5.80 | 6.68 | 0.77 | 0.32 | 0.03 |
|  | Microsimulation | 3.67 | 6.52 | 9.38 | 0.82 | 0.58 | 0.29 |
| RMST, restricted mean survival time; FC, fludarabine and cyclophosphamide; RFC, rituximab, fludarabine, and cyclophosphamide. | | | | | | | |